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Abstract
Background: Self-monitoring of hypertension is associated with lower systolic blood pressure (SBP). However,
evidence for the use of self-monitoring to titrate antihypertensive medication by physicians is equivocal.
Furthermore, there is some evidence for the efficacy of telemonitoring in the management of hypertension
but it is not clear what this adds over and above self-monitoring. This trial aims to evaluate whether GP
led antihypertensive titration using self-monitoring results in lower SBP compared to usual care and whether
telemonitoring adds anything to self-monitoring alone.
Methods/Design: This will be a pragmatic primary care based, unblinded, randomised controlled trial of
self-monitoring of BP with or without telemonitoring compared to usual care. Eligible patients will have
poorly controlled hypertension (>140/90 mmHg) and will be recruited from primary care. Participants will
be individually randomised to either usual care, self-monitoring alone, or self-monitoring with telemonitoring. The
primary outcome of the trial will be difference in clinic SBP between intervention and control groups at 12 months
adjusted for baseline SBP, gender, BP target and practice. At least 1110 patients will be sufficient to detect a difference
in SBP between self-monitoring with or without telemonitoring and usual care of 5 mmHg with 90% power with an
adjusted alpha of 0.017 (2-sided) to adjust for all three pairwise comparisons. Other outcomes will include adherence
of anti-hypertensive medication, lifestyle behaviours, health-related quality of life, and adverse events. An economic
analysis will consider both within trial costs and a model extrapolating the results thereafter. A qualitative sub study
will gain insights into the views, experiences and decision making processes of patients and health care professionals
focusing on the acceptability of self-monitoring and telemonitoring in the routine management of hypertension.
Discussion: The results of the trial will be directly applicable to primary care in the UK. If successful, self-monitoring
of BP in people with hypertension would be applicable to hundreds of thousands of individuals in the UK.
Trial registration: ISRCTN 83571366. Registered 17 July 2014
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Background
Blood pressure (BP) is a key risk factor for cardiovascu-
lar disease, the largest cause of morbidity and mortality
worldwide [1, 2]. A 10 mmHg reduction in BP is esti-
mated to lead to a 41% reduction in stroke and a 22%
reduction in coronary heart disease [3]. National and
international surveys suggest that, despite significant
improvements in recent years, BP control within the
population remains sub-optimal [4–7]. Self-monitoring
as an intervention has been shown to reduce BP [8, 9],
improve adherence to antihypertensive medication [10],
and reduce primary care consultation rates at no
additional cost [11]. Telemonitoring is associated with
reduced BP but there are limited data relevant to a UK
context, particularly with longer than 6 months follow-
up [12, 13]. Furthermore, the evidence concerning the
use of self-monitoring to guide GPs to titrate anti-
hypertensives is equivocal with one systematic review
finding the effect of self-monitoring on BP reduction
becomes non-significant when a medication titration
protocol is used [14].
The current (2004, updated 2006 & 2011) National
Institute for Health and Care Excellence (NICE)
guideline states: “the value of routinely using …
home (BP) monitoring devices has not been estab-
lished: their appropriate use in primary care remains
an issue for further research” [15]. This trial aims to
evaluate whether GP led antihypertensive titration
using self-monitoring results in lower systolic BP
(SBP) compared to usual care and whether telemoni-
toring reduces BP over and above self-monitoring
alone.
Methods and design
Study aims, research questions and outcomes
The primary aim of TASMINH4 is to compare the
management of hypertension in primary care using
self-monitored BP to make treatment decisions, with
or without telemonitoring, with usual care.
The trial has four main research questions:
1. Does self-monitoring guided titration of
antihypertensive medication, with or
without telemonitoring, lead to better BP
control in people with hypertension in
primary care?
2. Does self-monitoring guided titration of
antihypertensive medication with telemonitoring
lead to better BP control than self-monitoring
guided titration using paper-based recording
of BP?
3. Is the management of hypertension through
self-monitoring cost-effective?
4. What are the views of patients and their clinicians
regarding self-monitoring guided titration of
antihypertensive medication, with or without
telemonitoring?
The primary outcome of the trial will be the difference
in SBP (mean of 2nd/3rd readings, mmHg) at 12 month
follow-up between intervention and control adjusted for
baseline BP, gender, BP target, CVD history and practice.
Secondary outcomes (see Table 1, in each case also
adjusted for baseline values and co-variates) will include:
Blood Pressure Outcomes
– Difference in SBP at 6 months follow up between
intervention and control
– Difference in diastolic BP at six and 12 months
follow up between intervention and control
– All BP comparisons using mean of 2nd-6th readings
(BP-Tru automated blood pressure monitor,
(BP TRU BPM 200; BP TRU Medical Devices,
Coquitlam, BC, Canada) [16].
Table 1 Data collection throughout the trial
Baseline only:
1. Demographic questions: including age, race, marital status,
occupation, and education
2. Duration of hypertension [from notes]
3. Past medical history [from notes and corroborated by patients]
4. Contraindications to anti-hypertensives
5. Short orientation memory test [22]
6. Height
Baseline and follow-up:
1. New medical history (in last 6/12 months)
2. Blood pressure (sitting plus standing)
3. Current anti-hypertensive medications including complementary
herbal or dietary supplements for BP lowering
4. Weight and waist circumference
5. Symptoms part plus short form of Illness Perception Questionnaire [23]
6. Short-form of the State-Trait Anxiety Inventory [24]
7. EQ-5D 5L [25]
8. BP measurement preference [26] [Baseline and 12 m follow up only]
9. Medication Adherence Rating Scale (MARS) Questionnaire [27]
[Baseline and 12 m follow up only]
10. Beliefs about Medicines Questionnaire [28] [Baseline and 12 m follow
up only]
11. Stanford Expectations of Treatment Scale (SETS) Items 1–6 [29]
[Baseline and 12 m follow up only]
12. Lifestyle questions: alcohol (Audit-C [30]), diet (Short Food Frequency
Questionnaire [31]), exercise (Godin Leisure-Time Exercise Questionnaire
[32]), smoking (Smoking tool kit [33]) [Baseline and 12 m follow
up only]
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Tertiary Outcomes
Adverse events
– Clinical Events: admissions, cardiovascular
events, deaths
– Anxiety
– Side effects of medication
Medication Outcomes
– Medication prescription: both number and defined
daily dose
– Adherence to medication
– Beliefs about medicines, expectations of treatment,
illness perceptions
Fidelity to intervention
– GP fidelity to medication titration protocol
– Patient fidelity to monitoring regime
Lifestyle
– Alcohol, diet, smoking, exercise
Quality of Life
– EQ-5D-5L
Economic Outcomes:
– Resource use and costs
– Within trial effectiveness will be assessed in terms of
cost per 1 mmHg blood pressure reduction. Long
term cost effectiveness will be assessed by linking
differences in blood pressure observed in the trial to
cardiovascular events with a lifetime horizon.
Qualitative Analysis:
The views of patients and clinicians will be assessed
through depth interviews in the qualitative sub study
(see below for further details).
Study design and setting
TASMINH4 is a pragmatic unblinded individual patient
randomised controlled trial with automated ascertain-
ment of outcome and embedded economic and qualita-
tive analyses.
Study population
The study population will comprise people with poorly
controlled hypertension managed in primary care.
Eligibility criteria will be: age over 35 years, on the
hypertension register, not already taking more than 3
anti-hypertensive agents, BP above 140/90 mmHg at the
baseline clinic, and on a stable dose of current antihy-
pertensive medication for at least 4 weeks prior to trial
entry. Exclusion criteria will be orthostatic hypotension
(20 mmHg or more systolic drop after standing for one
minute, in order to avoid adverse events), BP not man-
aged by their GP (limited possibility of antihypertensive
titration), diagnosed atrial fibrillation (automated moni-
tors not validated), unwilling to self-monitor, dementia
or score over 10 on the short orientation memory con-
centration test (inability to undertake self-monitoring),
female participant who is pregnant, lactating or planning
pregnancy during the trial (management of essential
hypertension in pregnancy is different), the partner or
spouse of an individual already randomised in the trial
(to avoid clustering within families), Chronic Kidney
Disease (CKD) grade four or worse, any grade of CKD
with proteinuria (both may have different BP targets),
participants who have participated in another research
trial involving antihypertensive medication in the past
4 weeks.
Potentially eligible patients will be identified from gen-
eral practices via the UK Clinical Research Network
(CRN). GP surgery staff supported by the research team/
CRN will conduct a practice-based computer search to
identify patients that fulfil the eligibility criteria. GPs will
be asked to check these computer generated lists and to
remove people who are known to have terminal ill-
nesses, those not managed by the GP and those thought
to be unsuitable for the study in the opinion of the GP.
The remainder will receive a postal invitation with a
reminder after two weeks. Those wishing to decline
participation may voluntarily return a form detailing
basic demographic details as well as their reasons for
declining.
Baseline clinics
Patients will attend an initial baseline clinic where the
study will be explained, informed consent gained, clinical
measurements (height, weight, and BP) taken, demo-
graphics, past medical history, and key health behav-
ioural and attitudinal related data collected (Table 1) by
a trained researcher (either a research nurse, trained
practice nurse, or member of the research team).
Measurement of BP will use a validated automated elec-
tronic sphygmomanometer (BP TRU BPM 200). After
five minutes of rest, six seated BP readings will be taken
at 1-min intervals, of which the mean of the 2nd and 3rd
reading will comprise the primary outcome. Randomisa-
tion will take place at the end of the baseline clinic.
Randomisation
Patients will be randomised into one of three groups: self-
monitoring alone, self-monitoring and telemonitoring, or
Franssen et al. BMC Cardiovascular Disorders  (2017) 17:58 Page 3 of 8
usual care (1:1:1), using a fully-validated internet based
randomisation system with manual telephone-based back
up. Randomisation will be stratified by practice and mini-
misation, with a non-deterministic algorithm, will be used
to ensure balance in baseline BP, gender and BP target
(standard, older person or diabetic) across the groups.
Intervention and control groups
Usual care will consist of the participant’s BP being
measured by their GP and/ or nurse at their practice,
and adjustment of medication based on these measure-
ments at the discretion of the health care professional.
The participants in the self-monitoring groups
(self-monitoring alone and self-monitoring with tele-
monitoring) will be trained to monitor their BP using
an automated electronic sphygmomanometer (Omron
M10-IT) [17]. Patients will self-monitor BP daily for
the first week of each month of the study. They will
take their BP twice in the morning and evening (i.e.
four times in all per day) [15]. Participant training
will include instructions as to what to do in the pres-
ence of a high or low reading, using a guideline that
contains simple colour-coded instructions. Very high
or very low readings that persist when a third reading
is taken five minutes after the second reading will
trigger the patient to contact their practice for further
advice.
Medication reviews
All participants will be asked to book an appointment
approximately one week later with the GP or practice
nurse for a medication review. For the patients in the
usual care arm, the GP will review the medication based
on BP measurements taken in the clinic. The patients in
the self-monitoring arms will monitor their BP for a
week and bring the readings to their appointment. The
GP will base the medication review on the readings done
by the patient at home. After the medication review the
GP/ nurse will register the patients in the telemonitoring
arm on the text system and will train the patient in
using the system.
Communication of home readings
Self-monitoring group
Participants in the self-monitoring group will complete a
simple two-part carbon copy form each month to record
their daily BP readings, one copy to be kept by the pa-
tient, and one posted to the practice in a reply-paid en-
velope. The GP/ nurse will be asked to review these BP
readings each month to determine whether a change in
medication is required and the GP/ nurse will contact
the patient if a medication change is required. At follow-
up (6 and 12 months), data from participants’ BP
machines will be uploaded and sent to the research team.
Telemonitoring group
Participants will be trained in the use of the telemonitor-
ing equipment before commencing. Participants in the
telemonitoring group will send their readings to a secure
centralised database using a free SMS text message with
web-based data entry back up. They will receive a re-
minder the day before their week of measurements, and
two additional reminders in the week if no measure-
ments are received by the system. Mean BP will be cal-
culated automatically. High or low readings will trigger
text alerts to the patient to contact their surgery for a
BP check. The GP/ nurse will review the readings on a
monthly basis via a web-based interface to determine
whether a change in medication is required and the GP/
nurse will contact the patient if a medication change is
required. At follow-up (6 and 12 months), data from
participants’ BP machines will be uploaded and sent to
the research team.
Target blood pressure
Target BP will be based on the NICE hypertension
guideline with adjustment downwards by 5/5 mmHg for
home as compared to office readings [18]. Thus people
without diabetes under 80 years will have a home target
of ≤135/85 mmHg; people over 80 years will have a
home target of ≤145/85 mmHg; finally, people with dia-
betes will have a home target of ≤135/75 mmHg [15].
People requiring lower than standard targets will be ex-
cluded (hence the exclusions for CKD4 and proteinuria)
(see Table 2).
Follow-up
All patients will be asked to attend two follow-up clinics;
1 at 6 months and 1 at 12 months. Each clinic will be
timetabled for no more than an hour, during which
patients will have their BP and weight measured by the
research team and will be asked to complete a question-
naire similar to the one completed at baseline. Partici-
pant flow through the trial is shown in Fig. 1. All data is
collected on a case report form especially designed for
the study.
Patients who withdraw will not be replaced, but asked
if they are prepared to attend follow-up clinics.
Table 2 Blood Pressure targets for the different groups for
home readings and for readings taken in clinic
BP target (mmHg) BP target (mmHg)
Readings Taken at home Taken in clinic
<80 years ≤135/85 ≤140/90
>80 years ≤145/85 ≤150/90
Diabetic ≤135/75 ≤140/80
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Sample size considerations
The study requires a total sample of 1110 patients to be
recruited with 370 patients in each arm. This is based
on an assumption of a common standard deviation of
17 mmHg and a three way pairwise comparison. At least
367 participants per group (allowing for 15% attrition)
would allow detection of a 5 mmHg difference between
the groups (i.e. standardised effect size = 0.3) with 90%
power and an adjusted alpha of 0.017 (2-sided) to ac-
count for all three pairwise comparisons. We estimate
that around 120–150 practices will be required to recruit
this size of sample, assuming an average list size of 7000,
with a prevalence of hypertension of 13%, of whom 16%
will respond to a trial invitation and 40% of these will be
eligible. This corresponds to around 7–10 patients per
practice of 7000 patients.
Statistical analysis
Analysis will be on an intention-to-treat basis. A mixed
model will analyse the primary outcome utilising data col-
lected at 6 and 12 months from randomisation, adjusting
for baseline BP measure and minimisation variables. An
advantage of the mixed model is that it implicitly accounts
for data missing at random. The model will include a ran-
dom intercept for each participant to account for the re-
peated measures on the same participant. Time and
randomised group will be fitted as fixed effects, with
minimisation variables, region and history of CVD fitted
as covariates. An interaction term between time and ran-
domisation group will be included so that possible differ-
ences of treatment effect can be assessed at each time
point. Similar methods will be used for other continuous
outcomes. The two self-monitoring groups will first be
compared to the usual care group. If both treatments are
found to be more effective than usual care, they will be
compared to each other.
Sensitivity analyses will be carried out to examine the
robustness of the results with different assumptions
about departures from randomisation policies and hand-
ling of missing data. A detailed statistical analysis plan
will be prepared before any analyses are undertaken and
before the trial database is locked.
Data management
Double data entry will be employed for all trial paper-
work. The second data entry person will resolve
Fig. 1 Flow through the trial
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differences between first and second pass (differences
will be identified at point of submission by the data
entry module within OpenClinica).
Potential risks
It is anticipated that the potential risks of this study are
low and similar to those attributable to usual care. A
particular issue is the possibility of increased anxiety
where a patient finds an excessively high or low reading.
The patient guideline will advise contact with the super-
vising physician or nurse in the case of excessively high
or low readings. Training of participants will cover
repeated measurements in the case of unusually high or
low readings and a study “Freephone” helpline will be
available in the guideline. Data on adverse events will be
collected.
Economic sub-study
The economic evaluation will comprise both a within-
trial analysis and model-based analysis to extrapolate be-
yond the trial results.
a) Trial-based analysis
NHS costs will be determined for health care re-
source use over the 12 month follow-up period of
the trial. Resource use will include primary care con-
sultations (GP and practice nurse visits), secondary
care referrals, hospital inpatient stays and antihyper-
tensive medications. Data on trial-specific resources
such as consultations, equipment for self-monitoring
and telemonitoring and training will also be col-
lected. Unit costs will be derived from published
sources.
The cost-effectiveness analysis will consider the cost per
additional 1 mmHg reduction in Systolic BP from baseline
to 12 months. A cost-utility analysis will determine the
cost per Quality-Adjusted Life Year (QALY) gained over
the same period, using patient responses to the EQ-5D 5L.
The results for both outcomes will be expressed in terms
of Incremental Cost-Effectiveness Ratios (ICERs). The
base case economic evaluation will adopt an NHS per-
spective. The analysis will also consider all three arms of
the trial, comparing self-monitoring with and without tele-
monitoring to usual care.
Sensitivity analysis will test the robustness of the
results. Key parameters will be varied to determine
the impact of changes on results. Non-parametric
bootstrapping and probabilistic sensitivity analysis
will be undertaken to explore uncertainty in the con-
fidence to be placed on the results of the economic
analysis and cost effectiveness acceptability curves
presented.
b) Model-based analysis
A Markov model-based analysis with patient level
simulation will consider long-term cost effectiveness by
linking intermediate outcomes (i.e. change in BP) to car-
diovascular events, and will consider the BP monitoring
options within the trial and usual care. The model will
determine the cost per additional QALY gained for alter-
native monitoring scenarios.
Data from the trial and literature will inform the prob-
ability of these events occurring and the risk reduction
afforded by the alternative strategies. Attached to each
health state will be associated health state utility values
in order that QALYs can be calculated. Quality of life on
each treatment strategy will be obtained from the trial
data on EQ-5D 5L, and previous studies will inform util-
ity values for cardiovascular disease health states. Costs
of monitoring and the therapies prescribed in each strat-
egy and acute and long term costs of cardiovascular
events will be obtained within the trial and from the
literature.
The base-case will be conducted from a health and
personal social services perspective. The model will be
run over patient lifetime, with costs and benefits dis-
counted at a rate of 3.5% [19]. In order to explore uncer-
tainties in the analyses, deterministic sensitivity analysis
will test the robustness of the model when varying key
model parameters and structural assumptions, including
assumptions around side effects of treatment and adher-
ence to medication. Probabilistic sensitivity analysis will
be undertaken to incorporate the uncertainty around
parameter values and quantify the overall decision un-
certainty, and inform whether further research is
required.
Qualitative sub-study
The qualitative component of the trial will gain insights
into the views, experiences and decision-making pro-
cesses of patients and health care professionals regarding
self-monitoring and telemonitoring in the routine man-
agement of hypertension.
It is anticipated that up to 30 patients and up to 30 cli-
nicians who have taken part in the trial will be inter-
viewed. Where carers were involved in the process of
hypertension care, they will be invited to join the patient
interviews. Participants will be selected purposively from
participating practices to ensure a maximum variety
sample reflecting the range of professional and partici-
pant characteristics [20]. Interviews will take place when
participants have had a minimum of 6 months trial
participation to ensure current relevance to study.
Consent will be sought from all patients, informal
carers/relatives and health care professionals taking part,
including for the use of anonymised quotes.
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The interviews will focus on identifying perceived bar-
riers and facilitators to implementing either the telemo-
nitoring or paper-based system in routine practice.
Decisional processes and information sharing between
patient, practitioner and practice staff relating to imple-
mentation will be further explored. Interviews will be
recorded and transcribed verbatim.
Interviews will be analysed thematically to bring out
both ‘articulated’ data (direct responses to questions on
the areas described above) as well as ‘emergent’ data
(new information which emerges from comparison of
themes) [21].
Discussion
This article describes the protocol for the TASMINH4
study, a randomised controlled trial assessing whether
GP led antihypertensive titration using self-monitoring
results in lower SBP compared to usual care and
whether telemonitoring reduces BP over and above self-
monitoring alone.
The results will provide data on the effects of self-
monitoring with or without telemonitoring as a
means of titrating blood pressure in UK primary care.
Secondary outcomes will include a process evaluation
and information about potential harms. Linked quali-
tative and economic work will aid understanding of
how these interventions have worked in practice and
cost effectiveness.
The results of the trial will be directly applicable to
primary care in the UK. If antihypertensive drug titration
in primary care using self-monitoring of BP is found to
be successful in the management of hypertension, then
it would be applicable to many hundreds of thousands
of individuals in the UK. Importantly the trial will also
inform the use (or not) of telemonitoring alongside self-
monitoring of BP, feeding into guidelines in the UK and
beyond.
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